NCT02902601View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 17, 2016

Primary Completion Date

June 2, 2017

Study Completion Date

June 7, 2017

Conditions
Depressive Disorder, Major
Interventions
DRUG

JNJ-54175446, 600 mg

Participants will receive JNJ-54175446, 600 mg as an oral suspension.

DRUG

JNJ-54175446, 150 mg

Participants will receive JNJ-54175446, 150 mg as an oral suspension.

OTHER

Placebo

Matching placebo to JNJ-54175446

Trial Locations (4)

Unknown

Berlin

Hamburg

Schwerin

Leiden

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02902601 - A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder | Biotech Hunter | Biotech Hunter